Natixis Advisors L.P. Raises Holdings in Qiagen (NYSE:QGEN)

Natixis Advisors L.P. increased its position in Qiagen (NYSE:QGEN) by 101.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 598,279 shares of the company’s stock after acquiring an additional 301,003 shares during the quarter. Natixis Advisors L.P.’s holdings in Qiagen were worth $25,983,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in QGEN. Wellington Management Group LLP grew its stake in Qiagen by 81.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company’s stock valued at $245,299,000 after buying an additional 2,709,030 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Qiagen by 33,220.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company’s stock valued at $58,435,000 after purchasing an additional 1,341,450 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Qiagen by 5.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 22,257,083 shares of the company’s stock valued at $901,412,000 after purchasing an additional 1,072,923 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Qiagen by 40.9% during the 3rd quarter. Jennison Associates LLC now owns 1,131,808 shares of the company’s stock valued at $45,838,000 after purchasing an additional 328,291 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Qiagen by 178.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 503,592 shares of the company’s stock worth $20,405,000 after purchasing an additional 322,607 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN stock opened at $42.98 on Friday. The firm has a 50 day simple moving average of $42.53 and a two-hundred day simple moving average of $42.75. The stock has a market cap of $9.81 billion, a PE ratio of 28.82, a P/E/G ratio of 3.64 and a beta of 0.42. Qiagen has a one year low of $34.74 and a one year high of $47.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.62.

Qiagen (NYSE:QGEN) last released its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. During the same quarter in the prior year, the firm earned $0.53 earnings per share. The firm’s revenue was down 5.4% on a year-over-year basis. On average, analysts predict that Qiagen will post 2.09 EPS for the current fiscal year.

Analysts Set New Price Targets

QGEN has been the subject of a number of recent analyst reports. Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $49.48 to $51.00 in a report on Friday, February 16th. Citigroup reduced their price objective on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research note on Thursday, February 8th. Stifel Nicolaus decreased their target price on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Qiagen presently has an average rating of “Moderate Buy” and an average target price of $50.95.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.